NETRIS Pharma Secures €7.25 Million in Horizon Europe Funding to Advance Phase 2b Clinical Trial in Head and Neck Cancer
Summary
NETRIS Pharma secured €7.25 million from Horizon Europe to fund a Phase 2b randomized clinical trial of its NP137 antibody in head and neck squamous cell carcinoma. The company will run the study with GORTEC, TTCC, and Université Libre de Bruxelles, with Dr. Jérôme Fayette leading the trial. The funding will support trial design, execution, and analysis as the company advances NP137 toward regulatory discussions. The announcement reinforces NETRIS Pharma’s clinical strategy around the netrin-1/EMT axis and its broader oncology pipeline.
Funding
Amount
None
Total raised
Date
May 28, 2026
Announcement date
Investors
-
Lead investors
Company
netrispharma.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected